SBHMY News and Press, Sino Biopharmaceutical Ltd ADR

2024-06-11 08:45:21 ET More on Sino Biopharmaceutical Limited Historical earnings data for Sino Biopharmaceutical Limited Dividend scorecard for Sino Biopharmaceutical Limited Financial information for Sino Biopharmaceutical Limited Read the full article on...

Sino Biopharm (1177.HK) Announces 2023 Annual Results HONG KONG, Mar 29, 2024 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results HONG KONG, Aug 25, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical ...

2023-08-13 07:00:00 ET Summary BeiGene and Bristol-Myers Squibb have completed the breakup of their partnership, with BeiGene regaining shares worth $340 million. Gracell Biotechnologies raised $100 million in a private placement to support the development of its CAR-T therapies. ...

2023-07-09 09:15:00 ET Summary Moderna is setting up operations in Shanghai to develop and manufacture mRNA products for the Chinese market, investing up to $1 billion. F-star Therapeutics has formed a collaboration with Takeda to develop Fcab domains for immuno-oncology targets, ...

2023-06-04 07:30:00 ET Summary Hangzhou Betta Pharma acquired greater China rights for a novel non-small cell lung cancer drug from Boston’s C4 Therapeutics in a deal worth up to $392 million. Shanghai’s Impact Therapeutics out-licensed global rights (ex-China) for t...

2023-04-10 00:38:00 ET Summary Duality Biologics (Suzhou) out-licensed global rights (ex-China) for two ADC candidates to BioNTech in a deal worth $170 million upfront and up to $1.5 billion in milestone payments. Shanghai HutchMed has completed the rolling submission of a US NDA ...

Sino Biopharm (1177.HK) Announces 2022 Annual Results HONG KONG, Mar 31, 2023 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the...

2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...

2023-03-13 00:55:00 ET Summary Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Harbour BioMed announced positive results from a China Phase III trial of its anti-FcRn mAb in patients ...